### **Overview** HealthCare Global Enterprises Ltd. (HCG) is the **largest provider of cancer care in India**, headquartered in **Bengaluru**. With a pan-India and African footprint, HCG operates a **network of specialized oncology hospitals and fertility centers**, offering **advanced, integrated cancer diagnosis and treatment services**. The company combines clinical excellence, technological innovation, and strategic expansion to deliver globally competitive outcomes at affordable costs. HCG also operates **7 fertility centers under the ‘Milann’ brand**, positioning itself as a diversified specialty healthcare player in **oncology and reproductive medicine**. --- ### **Corporate Structure & Subsidiaries** HCG has a **multi-tiered, international corporate structure**, leveraging subsidiaries and joint ventures: - **Indian Subsidiaries (wholly-owned)**: - Niruja Product Development & Healthcare Research Private Limited - HealthCare Global Senthil Multi Specialty Private Limited - Suchirayu Health Care Solutions Limited - **International Presence**: - Operates through **HCG (Mauritius) Pvt. Ltd.**, which owns **Healthcare Global (Africa) Private Limited**. - **Step-down subsidiaries** in **Kenya, Uganda, and Tanzania** via the Mauritius holding. - **Joint Venture**: - **Advanced Molecular Imaging Limited (Kenya)** – enhances diagnostic imaging capabilities in East Africa. - **Acquisitions**: - Acquired **SRJ CBCC Cancer Hospital (Indore)** and **Mahatma Gandhi Cancer Hospital & Research Institute (Vizag)** in 2024–2025, reinforcing acquisition-led growth. --- ### **Operations & Network (as of Nov 2025)** - **22 Comprehensive Cancer Centers** across **India and Africa** (India: 9 states; Africa: Nairobi, Kenya, and satellite centers). - **Specialized cancer hospitals in Vizag, Jharsuguda, and Odisha**, under the **Vizag Hospital & Cancer Research Centre group**. - **7 Milann Fertility Centers** – focused on assisted reproduction and reproductive health. - **International Expansion**: Operational presence in **Uganda, Tanzania, and Kenya**, with further regional expansion plans. --- ### **Strategic Focus & Differentiators** #### **1. Acquisition-Led Growth Strategy** - Shifted from organic to **acquisition-led expansion** to accelerate scale. - Completed key acquisitions of: - **SRJ CBCC Cancer Hospital (Indore)** – ₹30 crore revenue asset with 17–18% EBITDA margin. - **MGCHRI (Vizag)** – acquired 51% stake (planning 85%), **196-bed facility** with strong market share, LINAC, PET-CT, robotic surgery, and BMT unit. - Acquisitions are expected to add **200–300 bps to growth** and enhance regional clinical and operational synergies. #### **2. Technology & Innovation** - **Pioneer in advanced oncology technologies**: - First in **India and Asia** to launch **CyberKnife, TomoTherapy, Radixact, Versa HD, AI-driven Ethos Adaptive Radiotherapy**, and **MR-LINAC**. - **First in Asia** to complete **120+ clinical runs of Comprehensive Genomic Profiling (CGP)** across 1,000+ patients. - **AI, Digital Infrastructure & Precision Medicine**: - Invested in **private-cloud IT infrastructure** with **centralized EMR, HIS, ERP**. - Uses **Microsoft HoloLens 2** for **augmented reality (AR) guidance** in surgery and virtual consultations. - **Virtual Tumor Boards** connect **150+ oncologists weekly** across locations. - **Central Radiation Planning** ensures consistent treatment delivery. - **Digital pathology, PET-CT, and centralized genomics** support remote diagnostics. - **Robotic Surgery & Advanced Therapies**: - Deployed **Da Vinci robots** in Mumbai, Ahmedabad, Kolkata, and Borivali. - Offers **scalp cooling therapy**, **genetic counseling**, and **home/palliative care**. --- ### **Clinical Approach & Outcomes** - **Tumor Board Approach** (led by Dr. Ajai Kumar) – ensures evidence-based, multidisciplinary treatment planning. - **Integrated, organ-specific oncology model** – combines medical, surgical, and radiation oncology under one roof. - **Superior clinical outcomes**: - **Below 1% post-op mortality** (down from 3.4% in 2019). - Better results in **triple-negative breast cancer** vs. Western benchmarks. - **4,200+ CyberKnife procedures** at Bangalore COE – highest in India. - **Focus on early detection** – only 20% of cancers in India diagnosed early; HCG emphasizes screening and proactive care. --- ### **Financial & Operational Performance** #### **Revenue & Growth (Recent Trends)** - **12–14% YoY revenue growth** (Jun 2024), adjusting for MSR Bengaluru exit. - **Non-metro centers outperform metros**: - **15%+ ROCE in 10 non-metro centers**. - Higher **patient volumes**: 22,000 surgeries (non-metro) vs. 10,000 (metro). - **21% EBITDA margin (non-metro)** vs. 20% in metros. - **19% revenue CAGR in regional markets**. - **Profitability turnaround**: - EBITDA turned positive in **FY24** – from ₹25M loss to ₹27M gain (14% margin). - Kolkata center achieved **EBITDA breakeven in FY24**. #### **Digital Transformation** - **HCG Care App**: - Serves **56,000+ outpatients**. - Enables **remote consultations, records access, follow-ups, and early recurrence detection**. - **Virtual OPD and e-Consultations** – improve rural and post-treatment accessibility. --- ### **Leadership & Governance** - **Dr. Manish Mattoo** – Appointed **Executive Director & CEO (Aug 2025)**, bringing strategic leadership. - **Key Experts in Leadership**: - **Dr. Murali Krishna Voonna** – leads Vizag operations. - **Dr. Ajai Kumar** – leads Tumor Board and Institutional Research. - **Anjali Ajaikumar Rossi** – Executive Director (Strategy), driving quality, innovation, and operational excellence network-wide. --- ### **Research, Innovation & Partnerships** - **Institutional Research Committee (IRC)** – 30+ oncologists engaged in **clinical trials**. - **Clinical Partnerships** – with **Bristol Myers Squibb (BMS), AstraZeneca, IQVIA**. - **Genomics & Proteomics**: - Supports **personalized therapy** through **targeted sequencing, radiomics, and theranostics**. - Developing **ethnicity-specific treatment protocols** for Indian/Asian patients. - **Pilot Studies**: - **Low-dose Nivolumab (Immunotherapy)** for head & neck cancer. - **Non-invasive oral cancer detection** via saliva. --- ### **Key Financial Milestones** | Metric | Latest (as of FY25) | |-------|---------------------| | Revenue Growth (YoY) | ~14% (adjusting for closure) | | EBITDA Margin | ~21% (non-metro), 20% (metro) | | Network Size | 22 cancer centers, 7 fertility centers | | International Revenue | Recovering post-pandemic; targeting pre-COVID ×1.5x | | Acquisitions (Last 18 Months) | SRJ CBCC (Indore), Vizag Hospital, Radiant (Sambalpur pending) | ---